Adaptive Clinical Trials and Tools to Support Them

Tahel Ilan Ber, Dan Goldstaub, Raviv Pryluk

Company name PhaseV *

Website https://phasevtrials.com/ *

CEO name Raviv Pryluk*

CATEGORY: Health IT/Digital *

SESSIONS

• Is AI revolutionizing drug discovery and clinical development?

o Executive Summary Clinical trials are the most time-consuming and costly stages of drug development, and many trials fail not because the biology or treatment doesn't work, but because trials are not designed properly. PhaseV is innovating the drug development process to enable more efficient, precise, and successful clinical trials using its platform for the design and execution of adaptive clinical trials.

o Core Technology PhaseV's platform leverages advancements in reinforcement learning, causal ML and cutting-edge software to support the transition to adaptive trial design. The one-of-its-kind platform provides stakeholders in clinical development teams the ability to understand the impact of adaptive design on their trial, make informed and optimal decisions to meet their trial objectives and support the adaptation logic throughout execution.

o Product Profile/Pipeline We work across therapeutic areas and clinical development stages, designing trials from Phase 1 through 3, in oncology, immunology, metabolic disease, rare disease and more. Our work includes a focus on dose optimization, weighing toxicity and efficacy in early development phases and recommending the most suitable adaptation type for increasing chances of success and saving resources.

o Business Strategy PhaseV's novel methods and advanced technology enable detecting hidden signals in clinical data, flag risks or unique potential of assets in clinical development, and predict the chances of a drug to successfully complete the clinical pipeline. PhaseV's partners use the services to support costly decisions, minimize risks in the drug development market, and build the right portfolio.

o What's Next? We are currently expanding our Bayesian statistical offering as well as the types of adaptations our platform supports and expanding our network, beyond biotechs

and pharmas, to CRO’s, funds and additional players in healthcare that may benefit from de-risking trials, saving failed trials, drug repurposing and more.